BGB-3111-106
Completed
A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects
Beigene Study ID 
BGB-3111-106
ClinicalTrials.gov ID
Sex:
All
Age: 18 Years to 55 Years (Adult)
Accepts Healthy Volunteers? yes
No Study Documents
Sex:
All
Age: 18 Years to 55 Years (Adult)
Accepts Healthy Volunteers? yes
No Study Documents
BeiGene provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained byBeiGene Australia, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.
Click the link above to continue or CANCEL